The global modified antibody market size is valued at USD 3.10 billion in 2025 and is predicted to hit around USD 7.36 ...

Zanidatamab, a bispecific HER2-targeted antibody, delivered clinically meaningful and durable responses for patients with ...

Founded in 2022, Phrontline is among the first biotechnology companies globally to focus on bispecific antibody ADCs (BsAb-ADCs) and dual-payload ADCs. The company has built an end-to-end ADC platform ...

Tecvayli plus Darzalex led to an 83% boost to progression-free survival versus the current standard therapy in relapsed or ...

Avenzo Therapeutics Granted Fast Track Designation for AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate ...

Zanidatamab, a bispecific HER2-targeted antibody, delivered clinically meaningful and durable responses for patients with ...

Since 2015, Dana-Farber researchers have been participating in clinical trials that evaluate the use of bispecific antibodies for patients with non-Hodgkin lymphoma. Three bispecific antibody ...

Bambusa Therapeutics, Inc. ("Bambusa"), a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for immunology and inflammation (I&I), today announced the completion of ...

DUBLIN--(BUSINESS WIRE)--The "Global Bispecific Antibody Drug Conjugates Clinical Trials, Regulatory Approvals & Future Market Opportunity Outlook 2029" report has been added to ResearchAndMarkets.com ...

A new approach targets the B-cell pathway with bispecific antibodies, building on decades of research that establishes the role of B cells and self-reactive antibodies in lupus, systemic sclerosis, ...

Delhi, April 04, 2025 (GLOBE NEWSWIRE) -- Over the last two decades, immunotherapy has transformed treatment strategies across various medical fields. The effectiveness of monoclonal antibodies in ...

The FDA granted fast track designation to AVZO-103 for the treatment of patients with previously treated locally advanced or metastatic urothelial cancer.